Literature DB >> 17666249

Allergen vial mixing and immunotherapy: Risks of infections and vial contamination.

P Chase Lay1, Richard Bass, Sandra Y Lin.   

Abstract

OBJECTIVE: To study the risks of vial contamination and infection associated with immunotherapy vial mixing and injection. STUDY
DESIGN: Retrospective review of patient immunotherapy records from January 2000-June 2006.
SETTING: Tertiary care outpatient otolaryngology clinic.
RESULTS: Two hundred seventy-two patients were given 26,795 injections (average of 98.5 injections per patient). Three hundred ninety-nine total local reactions were reported by the subjects (1.49%; 95% CI 1.34%-1.63%). The majority (82%) of the local reactions occurred during escalation dosing. There were 23 episodes of wheezing or shortness of breath after injections (9.6 of 10,000). No patients experienced anaphylaxis. There was no documented skin or systemic infections as a result of the allergy injections. None of the patients experienced fever, discharge from the injection site, cellulitis, or required antibiotics.
CONCLUSION: This review of immunotherapy records revealed no complications of infection from the preparation and administration of immunotherapy performed in an outpatient clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666249     DOI: 10.1016/j.otohns.2007.02.012

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

Review 1.  Allergen immunotherapy extract treatment set preparation: making a safer and higher quality product for patients.

Authors:  Michael R Nelson; Maureen M Petersen; Wayne O Wolverton; Cecilia P Mikita
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

2.  Mining social media data to assess the risk of skin and soft tissue infections from allergen immunotherapy.

Authors:  Kimberly G Blumenthal; Maxim Topaz; Li Zhou; Tyler Harkness; Roee Sa'adon; Ofrit Bar-Bachar; Aidan A Long
Journal:  J Allergy Clin Immunol       Date:  2019-02-02       Impact factor: 10.793

3.  Allergen immunotherapy: No evidence of infectious risk.

Authors:  Diana S Balekian; Aleena Banerji; Kimberly G Blumenthal; Carlos A Camargo; Aidan A Long
Journal:  J Allergy Clin Immunol       Date:  2016-04-09       Impact factor: 10.793

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.